| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Executive Officer | Chief Executive Officer | Director +1 more
2 companies
Grant Pickering is Chief Executive Officer at PCVX and has filed Form 4s across 2 companies. Grant Pickering's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $26.2M at current prices.
Historically, Grant Pickering's trades have earned a middling insider score of 50/100 across 63 rated trades. Over a 12-month horizon, 38.3% of those trades were profitable, with an average 12-month return of -21.8%.
The biggest single holding is PCVX (~$26.1M) as Chief Executive Officer. The PCVX filings lean toward selling, a net 740,510 shares.
Grant Pickering has 85 Form 4 filings on record from December 2020 to September 2026, across 3 companies: Chief Executive Officer at Vaxcyte (PCVX), 2020–2026; Director at LeonaBio (LONA), 2026; Director at ATHA, 2022–2025.
The 277 reported transactions were 186 open-market sales, 49 option exercises, 17 tax withholdings and 16 option or other derivative awards, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 1 purchase worth about $60K and 57 sales worth about $39.6M.
The only open-market purchase was 25,000 shares of ATHA at an average $2.41 on March 30, 2023, about $60K.
The largest open-market sale was 55,000 shares of PCVX at an average $114.25 on October 1, 2024, about $6.3M. Twelve months later PCVX was down 67%.
All 32 sales since April 2023 were made under a Rule 10b5-1 trading plan, set up in advance.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jul 27, 2026 | PCVX Vaxcyte, Inc. | Chief Executive Officer | Sale+OE10b5-1 | 18,198 | $55.63 | $1,012,375.29 | -12.0% | +8.9% | - | |
| Jun 26, 2026 | PCVX Vaxcyte, Inc. | Chief Executive Officer | Sell10b5-1 | 24,237 | $55.22 | $1,338,269.91 | -15.3% | +0.7% | - | |
| Jun 18, 2026 | PCVX Vaxcyte, Inc. | Chief Executive Officer | Sale+OE10b5-1 | 24,461 | $52.50 | $1,284,204.75 | -3.9% | +14.2% | - | |
| Dec 9, 2024 | PCVX Vaxcyte, Inc. | Chief Executive Officer | Sell10b5-1 | 2,366 | $92.25 | $218,252.88 | -1.7% | -25.2% | -51.4% | |
| Dec 2, 2024 | PCVX Vaxcyte, Inc. | Chief Executive Officer | Sell10b5-1 | 15,000 | $92.45 | $1,386,794.41 | -3.2% | -21.3% | -51.2% | |
| Nov 7, 2024 | PCVX Vaxcyte, Inc. | Chief Executive Officer | Sale+OE10b5-1 | 2,366 | $103.89 | $245,796.25 | -1.7% | -13.0% | -59.4% | |
| Nov 1, 2024 | PCVX Vaxcyte, Inc. | Chief Executive Officer | Sell10b5-1 | 15,000 | $106.82 | $1,602,251.52 | -3.3% | -14.3% | -57.8% | |
| Oct 7, 2024 | PCVX Vaxcyte, Inc. | Chief Executive Officer | Sell10b5-1 | 7,098 | $109.21 | $775,154.41 | -4.9% | -20.7% | -61.4% | |
| Oct 1, 2024 | PCVX Vaxcyte, Inc. | Chief Executive Officer | Sale+OE10b5-1 | 51,622 | $114.47 | $5,908,955.20 | -10.3% | -29.0% | -67.1% | |
| Aug 23, 2024 | PCVX Vaxcyte, Inc. | Chief Executive Officer | Sale+OE10b5-1 | 15,000 | $78.98 | $1,184,766.70 | -3.0% | +11.4% | -59.3% |